Brief: CNS Pharmaceuticals Announces First Patient Enrolled In Spain In Ongoing Trial Evaluating Berubicin For Treatment Of GBM

CNS Pharmaceuticals

07/02/2023 13:48

Feb 7 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN
SPAIN IN
ONGOING POTENTIALLY PIVOTAL GLOBAL TRIAL EVALUATING BERUBICIN
FOR THE TREATMENT OF GBM
    * CNS PHARMACEUTICALS - ENROLLMENT CONTINUING TO PROGRESS
TOWARD
AN INTERIM ANALYSIS, PLANNED WHEN 30-50% OF SUBJECTS REACH
PRIMARY ENDPOINT EXPECTED MID-YEAR 2023
    * CNS PHARMACEUTICALS INC - ENROLLMENT WILL NOT BE PAUSED
DURING
THIS INTERIM ANALYSIS

Source text for Eikon:  ID:nPn2s21w0a 
Further company coverage:  CNSP.O